SCHEMBL4482240

SCHEMBL4482240

CCOC(=O)CNC(=O)Nc1n[nH]c2cc(-c3cccc(NC(C)=O)c3)ccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 9/20 0.61
TTK P33981 2/20 0.49
MAPK8 P45983 2/20 0.49
FGFR1 P11362 1/20 0.49
FGFR2 P21802 1/20 0.49
FGFR3 P22607 1/20 0.49
GSK3B P49841 4/20 0.49
GAK O14976 5/20 0.48
STK16 O75716 5/20 0.48
BMP2K Q9NSY1 5/20 0.48
HDAC6 Q9UBN7 1/20 0.48
RIOK3 O14730 1/20 0.47
PIP5K1C O60331 1/20 0.47
CDKL2 Q92772 1/20 0.47
RIOK1 Q9BRS2 1/20 0.47
MYLK2 Q9H1R3 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
MKNK1 Q9BUB5 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4485804 0.87 GSK3B (0.58) AAK1FGFR1FGFR2FGFR3GSK3B
SCHEMBL4504427 0.86 HDAC1 (0.61) FGFR1FGFR2FGFR3GSK3BHDAC6
SCHEMBL4479634 0.85 AAK1 (0.67) AAK1TTKMAPK8GSK3BGAK
SCHEMBL4488792 0.84 AAK1 (0.68) AAK1FGFR2FGFR3GSK3BGAK
SCHEMBL4484161 0.84 AAK1 (0.64) AAK1TTKMAPK8GSK3BGAK
SCHEMBL4491352 0.83 AAK1 (0.66) AAK1TTKFGFR2FGFR3GSK3B
SCHEMBL4494923 0.82 AAK1 (0.64) AAK1FGFR2FGFR3GSK3BGAK
SCHEMBL4492082 0.81 AAK1 (0.63) AAK1FGFR2FGFR3GSK3BGAK
SCHEMBL4559408 0.81 AAK1 (0.72) AAK1GSK3BGAKSTK16BMP2K
SCHEMBL12886082 0.81 AAK1 (0.66) AAK1TTKMAPK8FGFR1FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1506176-B1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PFIZER ITALIA SRL (IT) 2013-04-24 EP disclosed
US-7632854-B2 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2009-12-15 US disclosed
US-20060106083-A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2006-05-18 US disclosed
EP-1506176-A1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2005-02-16 EP disclosed
WO-2003097610-A1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106083-A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K15, MAP3K3, MAP3K20 AAK1 117/4885TTK 240/4885MAPK8 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.